Investment in blood cancer research has saved nearly 26 million years of life, but disparities remain
A retrospective study reveals that medical advancements in blood cancer treatment have saved 26 million years of life in the U.S. over the past 75 years. However, the research highlights persistent disparities in survival rates for patients with acute myeloid leukemia and Black individuals.
Why it matters
It underscores the success of therapeutic innovation while identifying critical gaps in healthcare equity that require targeted policy and research interventions.
edited by Sadie Harley , reviewed by Andrew Zinin
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Credit: Pixabay/CC0 Public Domain Over the past 75 years, advances in the treatment of major blood cancers have saved more than 25 million years of life in the United States, according to results of an analysis led by researchers at Blood Cancer United and published in Blood Advances . But the gains have not reached everyone equally: survival progress remains limited for people diagnosed with acute myeloid leukemia (AML) and for Black individuals across most major blood cancer types.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in